Levophacetoperane: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
{{Pharm-stub}} | {{Pharm-stub}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:Phacetoperane chemical structure.png|Levophacetoperane | |||
</gallery> | |||
Revision as of 01:19, 20 February 2025
Levophacetoperane is a stimulant drug of the phenethylamine and amphetamine chemical classes. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). Levophacetoperane was previously used as an anorectic or weight loss drug, but has since been discontinued.
History
Levophacetoperane was first synthesized in the 1960s and was used as an anorectic in the treatment of obesity. However, due to concerns about potential for abuse and addiction, it was discontinued.
Pharmacology
Levophacetoperane acts primarily as a norepinephrine-dopamine reuptake inhibitor, meaning it increases the levels of the norepinephrine and dopamine neurotransmitters in the brain by inhibiting their reuptake into neurons. This results in increased neuronal activity, which can lead to increased alertness and decreased appetite.
Side Effects
The side effects of Levophacetoperane are similar to those of other stimulant drugs and can include insomnia, nervousness, increased heart rate, and increased blood pressure. In rare cases, it can also cause psychosis or other serious mental health issues.
Legal Status
Levophacetoperane is currently a controlled substance in many countries due to its potential for abuse and addiction. In the United States, it is classified as a Schedule II controlled substance under the Controlled Substances Act.
See Also
-
Levophacetoperane
